About Evangelos Gragoudas, MD

Dr. Gragoudas is presently the Charles Edward Whitten Distinguished Professor of Ophthalmology at the Harvard Medical School and Distinguished Director of the Retina Service at Mass Eye and Ear. A prolific clinician-scientist, Dr. Gragoudas has published over 250 articles in peer-reviewed journals and written or authored more than 100 chapters, reviews, and books. Dr. Gragoudas is considered a world authority on the diagnosis and management of intraocular tumors. He pioneered the use of proton therapy in eye tumors, a treatment modality that has been proven to be extremely successful and has been used in many ocular oncology centers around the world.Dr. Gragoudas? second major contribution to Ophthalmology is the use of photodynamic therapy (PDT) for the treatment of AMD. He collaborated with Dr. Joan W. Miller on preclinical studies of PDT and based on large clinical trials, photodynamic therapy became the first widely used treatment for neovascular AMD.Dr. Gragoudas? third major contribution to Ophthalmology has been his work on ocular angiogenesis and anti-angiogenesis therapy. He worked with a group of ophthalmologists, including Drs. Joan Miller, Tony Adamis, Pat D?Amore and others to demonstrate the critical role of vascular endothelial growth factor (VEGF) in ocular neovascularization and went on to develop therapies targeting VEGF. In 2014, Dr. Gragoudas and his colleagues received the Champalimaud Vision Award for their work on using anti-angiogenesis drug therapy for the treatment of age-related macular degeneration. This award is considered the ?Nobel Prize? in Vision Research.He has received numerous honors and awards including: Academy Honor Award of American Academy of Ophthalmology; Retina Research Foundation prize of the Jules Gonin Lectureship; Research to Prevent Blindness Senior Scientific Investigators Award; Senior Achievement Award of American Academy of Ophthalmology; J. Donald M.Gass Medal of the Macula Society; the Arnall Patz Medal of the Macula Society; Mildred Weisenfeld Award for Excelence in Ophthalmology from ARVO.

Departments, Centers, & Programs:

Clinical Interests:




Mass Eye and Ear
243 Charles St.
Boston, MA 02114
Phone: 617-573-3515
Fax: 617-573-3678

Medical Education

  • MD, National and Kapodistrian University of Athens School of Medicine
  • Residency, Boston Medical Center

American Board Certifications

  • Ophthalmology, American Board of Ophthalmology


Dr. Gragoudas is a Senior Scientist and Co-Director of the Laser Laboratory, Angiogenesis Laboratory, and Retina Research Institute at Mass. Eye and Ear. He played a pivotal role in the development of proton bean therapy (PBT) for uveal melanoma, and performed both preclinical studies and the first clinical studies in patients. He continues to refine PBT and has taken a multidisciplinary approach to developing new strategies for managing uveal melanoma.Studies initiated in the early 1990s with Dr. Joan Miller produced a breakthrough for patients with wetAMD: photodynamictherapy (PDT) with verteporlin (VISudyne®). He and his colleagues identified the important role of vascular endothelial growth factor (VEGF) in ocular neovascularization, which formed the scientific basis for the present antiangiogenic treatments for neovascular AMD and other intraocular vascular diseases.


  • 1. Oxenreiter MM, Lane AM, Jain P, Kim IK, Gragoudas ES. Conservative management of suspicious melanocytic lesions of the iris. Graefes Arch Clin Exp Ophthalmol. 2019 Jun; 257(6):1319-1324.

    2. Lane AM, Kim IK, Gragoudas ES. Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma. JAMA Ophthalmol. 2018 09 01; 136(9):981-986. 

    3. Ung C, Laíns I, Silverman RF, Woods R, Lane AM, Papakostas TD, Husain D, Miller JW, Gragoudas ES, Kim IK, Miller JB. Evaluation of choroidal lesions with swept-source optical coherence tomography. Br J Ophthalmol. 2019 01; 103(1):88-93. 

    4. Papakostas TD, Morrison MA, Lane AM, Awh C, DeAngelis MM, Gragoudas ES, Kim IK. Genetic Risk Factors for Radiation Vasculopathy. Invest Ophthalmol Vis Sci. 2018 03 01; 59(3):1547-1553. 

    5. Kosmidou C, Efstathiou NE, Hoang MV, Notomi S, Konstantinou EK, Hirano M, Takahashi K, Maidana DE, Tsoka P, Young L, Gragoudas ES, Olsen TW, Morizane Y, Miller JW, Vavvas DG. Issues with the Specificity of Immunological Reagents for NLRP3: Implications for Age-related Macular Degeneration. Sci Rep. 2018 01 11; 8(1):461.

    View more

Reviews: Comments and Ratings